Mast cell tryptase: a new target for therapeutic intervention in asthma.
Tanaka
R D
RD
Department of Molecular Pharmacology, Arris Pharmaceutical Corporation, South San Francisco, CA 94080, USA.
Clark
J M
JM
Warne
R L
RL
Abraham
W M
WM
Moore
W R
WR
D000818:Animals; D017165:Ascaris suum / Q000276:immunology; D001985:Bronchial Provocation Tests; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D002217:Carbachol; D053818:Chymases; D004151:Dipeptides / Q000494:pharmacology / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D004802:Eosinophilia / Q000209:etiology / Q000473:pathology; D008407:Mast Cells / Q000187:drug effects / Q000201:enzymology*; D012130:Respiratory Hypersensitivity / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology / Q000473:pathology; D012697:Serine Endopeptidases / Q000502:physiology*; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D012756:Sheep; D053802:Tryptases
D004151:Dipeptides; C094700:N-(1-hydroxy-2-naphthoyl)arginyl-prolinamide; D015842:Serine Proteinase Inhibitors; D002217:Carbachol; D012697:Serine Endopeptidases; C083294:chymase 2; D053818:Chymases; D053802:Tryptases